Baxdrostat vs Lorundrostat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline

Baxdrostat · Baxfendy

Marketed by AstraZeneca and partners

Approved in Hypertensionsmall molecule
Reliable signal

NCT06034743 · Phase 3 · completed

The trial randomized 794 participants to baxdrostat or matching placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Both prespecified primary blood-pressure endpoints were met at Week 12: the reduction in seated systolic blood pressure was greater with 2 mg and 1 mg baxdrostat than with placebo, with p<0.0001 for each comparison.

Next expected readout: December 2026 · NCT07222917 (registry estimate)

Reported efficacy

Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy (Baseline to week 12): Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001). (met)

Result source: NCT06168409

Lorundrostat

Developed by Mineralys Therapeutics and partners

Phase 3 in Hypertensionsmall molecule
Reliable signal

NCT05769608 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled trial in 285 patients with uncontrolled hypertension that measured 24-hour ambulatory systolic blood pressure, the standard efficacy measure for this disease. The 50 mg lorundrostat dose lowered ambulatory blood pressure significantly more than placebo at week 12.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) (met)

Result source: NCT06153693

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBaxdrostatLorundrostat
Seated SBP, change-15.7 vs -5.8−9.9 vs placebo2 mg · wk 12 · n 266NCT06034743
7 other results
  • -14.5 vs -5.8 1 mg · wk 12 · n 264 · Phase 3 · primary NCT06034743
  • -3.7 vs 1.4 2 mg · wk 32 · n 172 · Phase 3 · secondary NCT06034743
  • -15.2 vs -5.4 2 mg · wk 12 · n 199 · Phase 3 · secondary NCT06034743
  • -14.9 vs -4.7 2 mg · wk 12 · n 108 · Phase 3 · secondary NCT06168409
  • -11.6 vs -2.4 2 mg · wk 8 · n 108 · Phase 3 · secondary NCT06168409
  • -12.1 vs -1.1 2 mg · wk 4 · n 108 · Phase 3 · secondary NCT06168409
  • -14.5 vs -5.4 1 mg · wk 12 · n 187 · Phase 3 · secondary NCT06034743
—Not posted · NCT06153693
24-hour ambulatory SBP, change-16.6 vs -2.6−14 vs placebo2 mg · wk 12 · n 89NCT06168409—Not posted · NCT06153693
Seated DBP, change-6.9 vs -3−3.9 vs placebo2 mg · wk 12 · n 266NCT06034743
4 other results
  • -7.6 vs -2.6 2 mg · wk 12 · n 107 · Phase 3 · secondary NCT06168409
  • -6.1 vs -0.5 2 mg · wk 8 · n 108 · Phase 3 · secondary NCT06168409
  • -5.4 vs 0.1 2 mg · wk 4 · n 108 · Phase 3 · secondary NCT06168409
  • -6.3 vs -3 1 mg · wk 12 · n 264 · Phase 3 · secondary NCT06034743
—Not posted · NCT06153693

Seated SBP, change

Baxdrostat
-15.7 vs -5.8−9.9 vs placebo2 mg · wk 12 · n 266NCT06034743
7 other results
  • -14.5 vs -5.8 1 mg · wk 12 · n 264 · Phase 3 · primary NCT06034743
  • -3.7 vs 1.4 2 mg · wk 32 · n 172 · Phase 3 · secondary NCT06034743
  • -15.2 vs -5.4 2 mg · wk 12 · n 199 · Phase 3 · secondary NCT06034743
  • -14.9 vs -4.7 2 mg · wk 12 · n 108 · Phase 3 · secondary NCT06168409
  • -11.6 vs -2.4 2 mg · wk 8 · n 108 · Phase 3 · secondary NCT06168409
  • -12.1 vs -1.1 2 mg · wk 4 · n 108 · Phase 3 · secondary NCT06168409
  • -14.5 vs -5.4 1 mg · wk 12 · n 187 · Phase 3 · secondary NCT06034743
Lorundrostat
—Not posted · NCT06153693

24-hour ambulatory SBP, change

Baxdrostat
-16.6 vs -2.6−14 vs placebo2 mg · wk 12 · n 89NCT06168409
Lorundrostat
—Not posted · NCT06153693

Seated DBP, change

Baxdrostat
-6.9 vs -3−3.9 vs placebo2 mg · wk 12 · n 266NCT06034743
4 other results
  • -7.6 vs -2.6 2 mg · wk 12 · n 107 · Phase 3 · secondary NCT06168409
  • -6.1 vs -0.5 2 mg · wk 8 · n 108 · Phase 3 · secondary NCT06168409
  • -5.4 vs 0.1 2 mg · wk 4 · n 108 · Phase 3 · secondary NCT06168409
  • -6.3 vs -3 1 mg · wk 12 · n 264 · Phase 3 · secondary NCT06034743
Lorundrostat
—Not posted · NCT06153693
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Baxdrostat: 3 of 4 rows · Lorundrostat: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBaxdrostatLorundrostat
Dropout rate
10.9%2 mga
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 5 more results
—2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
—2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
7.2%1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
5.5%2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
6.3%2 mg
NCT06336356 · Phase 2 · registry result, not featured evidence
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Discontinued due to AEs
—2 mga
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 5 more results
—2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
—2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
—1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
—2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
—2 mg
NCT06336356 · Phase 2 · registry result, not featured evidence
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Serious AEs
3.4%2 mga
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 5 more results
2.3%2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
4.8%2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
1.9%1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
0.9%2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
0%2 mg
NCT06336356 · Phase 2 · registry result, not featured evidence
3.4%
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Most frequent reported AEs
2 mga
hyperkalaemia 11.7% (placebo 2.7%)
hyponatraemia 3.8% (placebo 0.8%)
muscle spasms 3.8% (placebo 0.4%)
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 5 more results
2 mg
hyperkalaemia 9.9% (placebo 2.7%)
hyponatraemia 3.5% (placebo 0.8%)
nasopharyngitis 1.7% (placebo 2.3%)
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
2 mg
hyperkalaemia 16.1% (placebo 2.7%)
hyponatraemia 11.3% (placebo 0.8%)
muscle spasms 6.5% (placebo 0.4%)
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
1 mg
hyperkalaemia 6.1% (placebo 2.7%)
nasopharyngitis 3% (placebo 2.3%)
upper respiratory tract infection 2.7% (placebo 3.8%)
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
2 mg
hyperkalaemia 10.2% (placebo 2.8%)
headache 5.6% (placebo 2.8%)
hypotension 4.6% (placebo 0%)
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
2 mg
dizziness 6.3% (placebo 6.3%)
nausea 6.3% (placebo 0%)
vomiting 6.3% (placebo 0%)
NCT06336356 · Phase 2 · registry result, not featured evidence
hyperkalaemia 15.5% (placebo 3.5%)
glomerular filtration rate decreased 10.3% (placebo 3.5%)
hyponatraemia 5.2% (placebo 5.3%)
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Baxdrostat

Seated SBP -3.7 vs 1.4 placebo mmHg @ 32wk2 mg
absolute change · mmHg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 7 more results
-15.2 vs -5.4 placebo mmHg @ 12wk2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
-15.7 vs -5.8 placebo mmHg @ 12wk2 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
-14.9 vs -4.7 placebo mmHg @ 12wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-12.1 vs -1.1 placebo mmHg @ 4wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-11.6 vs -2.4 placebo mmHg @ 8wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-14.5 vs -5.4 placebo mmHg @ 12wk1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
-14.5 vs -5.8 placebo mmHg @ 12wk1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
Seated DBP -6.9 vs -3 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
show 4 more results
-7.6 vs -2.6 placebo mmHg @ 12wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-5.4 vs 0.1 placebo mmHg @ 4wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-6.1 vs -0.5 placebo mmHg @ 8wk2 mg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
-6.3 vs -3 placebo mmHg @ 12wk1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3
Seated SBP Control 40% (n=265) vs 18.7% (n=262) placebo @ 12wk2 mg
event count · % of participants
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 · converted to % from 106 Participants as posted
show 1 more result
39.4% (n=264) vs 18.7% (n=262) placebo @ 12wk*1 mg
NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 · converted to % from 104 Participants as posted
Ambulatory SBP -16.6 vs -2.6 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory Night SBP -16 vs -2.1 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory Day SBP -16.8 vs -2.7 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory SBP Control 70.6% (n=85) vs 16.7% (n=84) placebo @ 12wk2 mg
event count · % of participants
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 · converted to % from 60 Participants as posted
Ambulatory DBP -8.3 vs -1.5 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory Night DBP -7.9 vs -1.1 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Ambulatory Day DBP -8.4 vs -1.7 placebo mmHg @ 12wk2 mg
absolute change · mmHg
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3
Nocturnal SBP Dipping 40.4% (n=89) vs 29.5% (n=95) placebo @ 12wk2 mg
event count · % of participants
NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 · converted to % from 36 Participants as posted

Lorundrostat

AOBP SBP -9.253 vs -1.755 placebo mmHg @ 4wk
absolute change · mmHg
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Ambulatory SBP -7.9 mmHg @ 12wklorundrostat 50 mg arm
absolute change · mmHg
No placebo or comparator arm
NCT05769608 · Phase 2 · sponsor-reported, not registry data

Chronic Kidney Disease

Shared mechanism: Aldosterone synthase (CYP11B2) · full Chronic Kidney Disease pipeline

Baxdrostat · Baxfendy

Marketed by AstraZeneca and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07222917 (registry estimate)

No aligned efficacy figure on record for this race.

Lorundrostat

Developed by Mineralys Therapeutics and partners

Phase 2 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT06150924 · Phase 2 · completed

Explore-CKD was a randomized, double-blind, placebo-controlled, two-period crossover Phase 2 trial of lorundrostat 25 mg on top of an SGLT2 inhibitor in about 60 patients with hypertension and albuminuric chronic kidney disease. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure at week 4: -7.5 mmHg (p=0.0024), and the sponsor states the trial met the primary endpoint. Sources: CT.gov posted results and the Mineralys press release filed on SEC Form 8-K.

Reported efficacy

Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4 (Baseline to Week 4): Automated office systolic blood pressure at week 4: lorundrostat 25 mg -9.25 mmHg vs placebo -1.76 mmHg (CT.gov LS means, n=58 per period); placebo-adjusted -7.5 mmHg (p=0.0024) (Mineralys release, 17 Jun 2025, SEC 8-K). (met)

Result source: NCT06150924

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBaxdrostatLorundrostat
Kidney composite outcome—Trial running · NCT06268873—Not reported
UACR, % change—Trial running · NCT06268873—Not reported
eGFR slope—Trial running · NCT06268873—Not reported
Haemoglobin, change—Trial running · NCT06268873—Not reported

Kidney composite outcome

Baxdrostat
—Trial running · NCT06268873
Lorundrostat
—Not reported

UACR, % change

Baxdrostat
—Trial running · NCT06268873
Lorundrostat
—Not reported

eGFR slope

Baxdrostat
—Trial running · NCT06268873
Lorundrostat
—Not reported

Haemoglobin, change

Baxdrostat
—Trial running · NCT06268873
Lorundrostat
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Baxdrostat: registry results are on file for Chronic Kidney Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Baxdrostat: 0 of 4 rows · Lorundrostat: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLorundrostat
Dropout rate
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Discontinued due to AEs
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Serious AEs
3.4%
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Most frequent reported AEs
hyperkalaemia 15.5% (placebo 3.5%)
glomerular filtration rate decreased 10.3% (placebo 3.5%)
hyponatraemia 5.2% (placebo 5.3%)
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lorundrostat

AOBP SBP -9.253 vs -1.755 placebo mmHg @ 4wk
absolute change · mmHg
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Baxdrostat's landscape · Lorundrostat's landscape